- Johnson & Johnson entered a definitive agreement to acquire Atraverse Medical.
- Deal expected to close in Q2 2026; financial terms undisclosed.
- Atraverse's HOTWIRE Transseptal Access System is an FDA-cleared RF guidewire and generator for left atrial access.
- HOTWIRE has been used in nearly 3,000 clinical procedures.
Transaction
Johnson & Johnson has entered a definitive agreement to acquire Atraverse Medical, a privately held medical device company focused on left‑heart access and radiofrequency (RF) technology; the transaction is expected to close in Q2 2026, subject to customary closing conditions, and financial terms were not disclosed.
Device and clinical use
Atraverse’s HOTWIRE Transseptal Access System is an FDA‑cleared RF guidewire and generator for left atrial access, featuring impedance‑sensing automatic energy shutoff, compatibility with multiple sheaths, and clear tip visibility under intracardiac echocardiography; it has been used in nearly 3,000 clinical procedures.
Regulatory and risk considerations
The company cautioned that closing and post‑transaction outcomes are subject to risks including the possibility the deal may not complete as expected and uncertainties related to regulatory approvals, manufacturing, commercial performance, integration and legal or market developments.
